Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REJOICE-Ovarian 04: Raludotatug Deruxtecan Maintenance in Advanced Ovarian Cancer
NCT07776691Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2026
- Primary completion
- Mar 2032
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing Arm 1: R-DXd with or without bevacizumab with Arm 2: Standard of care (bevacizumab or observation only) (2 arms). Primary endpoints: Progression-Free Survival at 4 years and Overall Survival at 5.5 years. Started Sep 2026; status: recruiting.
02
Drugs
raludotatug deruxtecan
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT07776691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07776691.